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Abstract
Background The glucocorticoid (GC) hormone cortisol is
the end product of the hypothalamic–pituitary–adrenal axis
(HPA axis). Acute psychological stress increases HPA
activity and GC release. In humans, chronic disturbances
in HPA activity have been observed in affective disorders
and in addictive behaviour. Recent research indicates that
acute effects of GCs may be anxiolytic and increase reward
sensitivity. Furthermore, cortisol acutely influences early
cognitive processing of emotional stimuli.
Methods In order to extend such findings to more complex
emotional-cognitive behaviour, the present study tested
acute effects of 40 mg cortisol on motivated decision
making in 30 healthy young men.
Results Results showed that cortisol indeed increased
risky decision making, as predicted. This effect occurred
for decisions where making a risky choice could
potentially yield a big reward. These results are dis-
cussed with respect to currently proposed mechanisms
for cortisol’s potential anxiolytic effect and GCs’
involvement in reward systems.
Keywords Cortisol . HPA axis . Emotion . Anxiolytic .
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Introduction
The glucocorticoid hormones (GCs; cortisol in humans)
are produced as the end product of the hypothalamic–
pituitary–adrenal axis (HPA axis). After a physiologic or
psychological stressor, corticotropin-releasing factor
(CRF), synthesised in the paraventricular nucleus of the
hypothalamus, is released into the anterior pituitary,
which responds by increasing its output of adrenocorti-
cotropin hormone (ACTH). ACTH is then released into
the bloodstream and stimulates the release of cortisol by
the adrenal glands. When central cortisol concentrations
are elevated to stress levels, cortisol binds to GC
receptors (GRs), whose density is purportedly highest
in limbic and prefrontal areas where they probably
influence reciprocal prefrontal-limbic circuits of emotion
regulation (de Kloet et al. 1999; Sapolsky 2000; de Kloet
et al. 2005; Ochsner and Gross 2005; Urry et al. 2006).
Because of the involvement of the HPA axis in psycho-
logical stress, its relation to psychopathology has been
studied extensively. Chronic HPA dysregulation (mainly
hypercortisolism) has been reported for mood and anxiety
disorders (Yehuda et al. 1996; Yehuda 2001; Young and
Breslau 2004; Takahashi et al. 2005; Mantella et al. 2008;
Vreeburg et al. 2009). Addictive behaviour is also
associated with disturbances of HPA functioning and
HPA-induced sensitisation of the dopaminergic (DA)
mesolimbic ‘reward’ system (Marinelli and Piazza 2002;
Koob and Kreek 2007; Sinha 2008). Acute effects of GCs
may also contribute to increased reward-seeking and risk-
taking behaviour related to substance abuse and patholog-
ical gambling (Marinelli et al. 1998; Mantsch and Katz
2007; Wohl et al. 2008; van den Bos et al. 2009). For
stress-related psychopathology, the observed long-term
alterations of HPA functioning may be partly due to
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dysregulation of the HPA negative feedback system as a
result of unduly wear and tear on GRs (Yehuda 2004).
Much less is known about acute effects of cortisol on
emotion regulation and the manifestation of negative
affect, sensitivity to punishment and anxiety.
Several recent publications suggest that exogenous GCs
may reduce fear and biassed attentional and working-
memory processing of threat-related stimuli (Soravia et al.
2006; Het and Wolf 2007; Putman et al. 2007a, b; Oei et al.
2009; Vasa et al. 2009). This may be taken to suggest that
cortisol acutely alters cognitive processing (attention,
working memory, or memory retrieval) of threat- and
withdrawal-related negative arousing information (see
Putman et al. 2007a; de Quervain and Margraf 2008).
However, it may also be the case that cortisol acutely
influences bottom-up affective state, resulting in altered
performance on sensitive emotional-cognitive experimen-
tal tasks only as a secondary effect. This may not be
restricted to anxiolytic-like effects, but cortisol may also
promote a more reward-driven or approach-motivated
affective state. Animal models indeed suggest that high
levels of GCs increase reward- and approach-related
behaviour, likely due to increased DA activity (Marinelli
et al. 1998; Marinelli and Piazza 2002; Mikics et al.
2007).
Hence, the present study sought to establish if cortisol
acutely influences performance on a motivated decision-
making task wherein choice behaviour is influenced by
sensitivity to cues of punishment and reward. This
motivated decision-making task (Rogers et al. 2003)
presents subjects with 80 rounds of a gambling game in
which they have to choose to play a control gamble with a
fixed expectancy value or to play experimental gambles,
which vary in their associated potential losses, potential
gains and the probability of losing/winning. Choice
between playing the control gamble or the experimental
gamble is dictated by the perceived attractiveness of the
experimental gamble relative to the control gamble and so
depends on the attention that subjects pay to these cues of
potential punishment and reward and on how they weigh
their relative importance. This task has been utilised
repeatedly to assess effects of different psychopharma-
logical manipulations (e.g. Rogers et al. 2003, 2004;
Antypa et al. 2009). Since cortisol may also acutely
promote reward-driven behaviour (though there is less
empirical support for such a prediction from research in
humans), we also tested if cortisol administration would
result in increased sensitivity to reward. No effects on self-
reported state anxiety were expected (as also reported in,
for instance, Buchanan et al. 2001; Abercrombie et al.




Thirty healthy young men were recruited on campus and
were paid for their participation. Exclusion criteria were
drug use, habitual smoking, alcoholism, any past or
current psychiatric, endocrine or neurological illness and
excessive physical exercise. One participant demonstrat-
ed abnormal performance on the decision-making task
(see below) and only data of the 29 remaining men are
reported. Mean (M) age was 22.7 years [range, 20–30
with a standard deviation (SD) of 2.5]. The study was
approved by the local review board, and all subjects
provided written informed consent.
Design and procedures
Performance on various instruments was measured after
subjects were orally administered two different capsules,
identical in appearance, containing 40 mg hydrocorti-
sone+320 mg Primogel or 360 mg Primogel on two
separate testing sessions in a double-blind, placebo-
controlled crossover design. Order of drug administra-
tion was counterbalanced across the subjects with 15
subjects receiving placebo on the first day of testing and
14 subjects receiving cortisol on the first day; (wash-
out≥72 h). Curvilinear dose–response effects of GCs
have been reported for some cognitive effects of
cortisol. Buchanan et al. (2001) compared effects of 5
and 20 mg cortisol on a psychophysiological fear index
and also suggested a nonlinear dose–response with
apparent fear-reducing effects after the higher dose.
The present dose of 40 mg was chosen as the highest
level tested so far in human research for anxiolytic-like
effects. In addition, this administration procedure is
exactly as in our previous studies (Putman et al.
2007a, b, 2009). Testing was done between 1300 and
2000 hours at the same time on both days. Subjects
were required to refrain from intake of any nutrients for
at least 1.5 h prior to the start of the lab session. On
arrival, they first completed a questionnaire to assess
state anxiety (the STAI-s; van der Ploeg et al. 1980;
Spielberger 1983) after which the capsule was adminis-
tered. One hour later, another STAI-s was administered,
after which computerised testing began. Participants then
performed two experimental tasks designed to assess
attentional processing of neutral and emotional pictorial
stimuli, some of which may have been stressful to watch
(data reported elsewhere). The decision-making task was
administered last, approximately 2 h after capsule
administration.
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Decision-making task
This task contains 80 trials in which subjects have to
choose between two gambles with the aim of earning as
many game credits as possible. Coloured vertical bars of
varying length indicate the probability of winning/losing,
and the amount of credits that can be gained/lost is
indicated at the top and bottom of the bars. Subjects were
told that they would be paid a small amount of money for
earned game credits to increase motivation to perform well
on the task. Each trial lets the participant choose between a
control gamble and an experimental gamble. For all trials
other than the wins only and losses only trials (see below),
this control gamble predicts a 0.5 probability of winning
and a 0.5 probability of losing ten credits. Experimental
gambles vary in the probability of losing or winning (0.4
probability of losing versus 0.6 probability of losing), the
amount of expected gains (30 versus 70 credits) and the
amount of expected losses (30 versus 70 credits), yielding a
total of eight trial types that are each presented eight times
(see Table 1). In addition, there are eight ‘wins only’ and
eight ‘losses only’ trials. Wins only trials present the subjects
with a choice between a guaranteed win of 30 credits and a
gamble with 0.5 probability of winning 60 credits versus a 0.5
probability of winning nothing. The losses only trials present
a choice between a guaranteed loss of 30 credits and a gamble
representing a 0.5 probability of losing nothing and 0.5
probability of losing 60 credits. Typically, subjects choose the
guaranteed win in wins only trials and gamble on the losses
only trials. Order of trial types is randomised within four
continuously presented blocks of 20 trials presenting each trial
type twice per block. Dependent measures are proportionate
choice scores—the number of times the participant chooses a
certain experimental gamble relative to the frequency of
occurrence of that trial type. For the wins/losses only trials,
proportionate scores reflect the number of times the subjects
chose the guaranteed win/loss relative to the number of trials
of that condition.
Data reduction
Data from one participant were discarded; this participant
took on average more than 13 s to choose on one of the
testing days versus an average of approximately 2 s for the
other subjects. Distributions of raw, log-transformed and
arc sine-transformed performance scores for the decision-
making task all differed significantly from normal, so only
non-parametric statistical tests were performed for this
experimental task. In order to test interactions between
various conditions, contrast scores were calculated by
subtracting the number of proportionate choice scores for
various trial types. To test the effects of drug on probability
of losing, scores for high probability of losing were
subtracted from scores for low probability of losing for
the two drug conditions separately. To calculate the
expected gains contrast score, scores for low expected
gains were subtracted from scores for high expected gains.
An expected losses contrast score was similarly calculated
for high versus low expected losses. Note that for all these
contrast scores, larger scores indicate stronger preference
for less risky and more rewarding choices.
Within-subject comparisons between the various propor-
tionate choice scores and contrast scores were performed with
Wilcoxon rank tests. Between-subject comparisons for the
effects of order of administration (either placebo or cortisol on
the first day of testing) were performed with Mann–Whitney
U tests, but since no relevant comparisons showed an effect
of order, these tests are not further mentioned below. State
anxiety measures and salivary cortisol concentrations were
tested in repeated measures ANOVA’s with drug (2; placebo
versus cortisol) and time (2; before and after drug adminis-
tration) as within subject factors. Initially, order was entered
as a between-subject factor, but since order showed no
effects, it was removed from the analyses and is not further
reported below. Paired-sample t tests were used for simple
mean comparisons of cortisol concentrations.
Results
Cortisol
One saliva sample for one participant was lost (the pre-
administration sample in the placebo session). A repeated
Table 1 The eight conditions in the decision-making task where
participants have to chose between playing a control gamble or an
experimental gamble
Proportionate Choice Trials
Trial number Probability Expected gains Expected losses
1 High (60%) Large (70) Large (70)
2 Small (30)
3 Small (30) Large (70)
4 Small (30)
5 Low (40%) Large (70) Large (70)
6 Small (30)
7 Small (30) Large (70)
8 Small (30)
The control gamble predicts a 0.5 probability of winning and a 0.5
probability of losing ten credits. Experimental gambles vary in the
probability of losing/winning, the amount of expected gains and the
amount of expected losses, yielding a total of eight trial types
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measures ANOVA was performed with drug and time as
within-subjects factors and salivary cortisol concentrations
as dependent variable. This showed a significant main
effect of drug [F(1,27)=53.96; p<0.001], a significant main
effect of time [F(1,27)=52.84; p<0.001], and a significant
drug×time interaction [F(1,27)=55.68; p<0.001]. The
main effects of drug and time are carried by the high
cortisol concentration in the post-administration sample in
the cortisol condition. In the placebo condition, mean
cortisol concentration dropped from 7.73 nmol/L before
administration to 3.89 nmol/L after administration, ~1 h
later [t(27)=3.17; p<0.005]. In the cortisol condition,
mean cortisol concentration rose from 6.47 nmol/L
before administration to 116.4 nmol/L after administra-
tion [t(28)=7.44; p<0.001]. Post-administration cortisol
concentrations differed significantly between placebo and
cortisol conditions [t(28)=7.50; p<0.001].
State anxiety
STAI-s data for one participant were removed before
analyses because his STAI-s scores were extremely high
(>2 SDs above the mean on all measurements). For the
remaining subjects, a repeated measures ANOVAwith time
(before or after drug administration) and drug (placebo or
cortisol) as within-subject factors and STAI-s score as
dependent variable was performed. This showed no main
effect of drug [F(1,27)=0.063; p>0.05], no time×drug
interaction [F(1,27)=0.140; p>0.05], but a borderline
significant main effect of time [F(1,27)=4.185; p<0.1].
This trend-level main effect reflected a slight drop in STAI-
s between the first and second measurement across both
drug conditions: from M=30.9 (SD=5.4) to M=29.8 (SD=
5.5).
Gambling task
Median proportionate choice scores are presented in
Fig. 1a. Cortisol had no effect on overall frequency of
choice for experimental gambles (z=0.901; p>0.05). Sub-
jects more often preferred to gamble on the losses only than
on the wins only trials (z=3.977, p<0.001), but this was not
influenced by drug condition (z=0.299; p>0.05). More
experimental gambles were made for trials with small
expected losses than large expected losses (z=4.5345; p<
0.001). Drug condition had no significant effect on the
expected losses contrast score reflecting this risk avoidant
choice pattern (z=0.272; p>0.05). More experimental
gambles were made for trials with large expected gains
than for trials with small expected gains (z=4.628; p<
0.001). The expected gains contrast score reflecting this
reward-driven choice pattern was not influenced by drug
condition (z=1.039; p>0.05). More experimental gambles
were made for trials with a low probability of losing than
for trials with a high probability of losing (z=4.705; p<
0.001). Drug condition significantly influenced the proba-
bility of losing contrast score (z=2.106; p<0.05). Subjects
made more high-risk experimental gambles after cortisol
than after placebo. To clarify the nature of this effect of
drug, low and high probability of losing conditions were
analysed separately. Although cortisol had no effect on
choice pattern in the low probability of losing condition (z=
0.396; p>0.05), it significantly increased risk-seeking when
the probability of losing was high (z=1.763; p<0.05; one
tailed). We further explored this effect and analyses of the
separate trial types with a high probability of losing showed
that cortisol significantly increased the number of experi-
mental gambles of the most risky kind, i.e. when there was
a high probability of losing a large amount of credits (z=
2.519; p<0.025), especially when there was also a large
possible gain (z=2.802; p<0.005). Since this last test
concerns effect of cortisol on but one of eight experimental
trial types, it is important to note that it also proves
significant when using a Bonferroni-corrected alpha of
0.006 (see Fig. 1b).
Discussion
Our main hypothesis was that 40 mg of cortisol would
acutely decrease punishment-sensitive behaviour on the
gambling task. We also thought it was possible that cortisol
would increase reward-sensitive behaviour. Results showed
that cortisol changed motivated decision-making in a
manner compatible with both notions.
Analysis of salivary cortisol samples confirmed that the
cortisol manipulation was successful in significantly raising
cortisol concentrations to levels very similar to those
reported earlier for single oral 40 mg administrations (see,
e.g. Abercrombie et al. 2003; Putman et al. 2007a). Results
also showed a slight cortisol drop between the first and
second salivary samples in the placebo condition, which
probably reflects normal diurnal variation and/or habitua-
tion to the slight initial stress of coming to the lab for an
administration study (cf. Putman et al. 2007a).
As expected, no effect on self-reported anxiety was
observed. Only under very stressful circumstances (expo-
sure to phobic stimuli, exposure to a strong laboratory
stressor, or yohimbine-induced panic attack; Soravia et al.
2006; Het and Wolf 2007; Vasa et al. 2009) does cortisol
seem to influence self-reported affective state. Several
studies in healthy participants have reported that admin-
istrations of up to 40 mg cortisol does affect performance
on more sensitive experimental measures of affect and
emotional cognition in the absence of effects on non-
challenged self-reported affective state (e.g. Tops et al.
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2003, 2006; Putman et al. 2007a, b; Oei et al. 2009). This
suggests that cortisol does not work by directly altering
affective state but, rather, by altering the cognitive process-
ing of emotional information that people encounter during
their ongoing interactions with the environment [see de
Quervain and Margraf (2008) for a different instance of
such a biological-cognitive hypothesis, which applies
specifically to phobic memories and also see Harmer
(2008)].
Presently, as expected, cortisol reduced the influence of
perceived probability of losing on performance of the
gambling task. Although subjects typically shun the
gambles with a high probability of losing compared to
gambles with a low probability of losing, this risk-avoidant
behaviour was reduced by cortisol. Rogers et al. (2004)
reported that administration of a beta-adrenergic antagonist
had the clearest effect on performance of this task when the
probability of losing as well as the amount of potential
losses were high, as was presently found. Interestingly,
administration of such beta-adrenergic antagonists tends to
acutely increase cortisol levels (see, e.g. Kizildere et al.
2003). Closer inspection of the present effect on the
compound variable of probability of losing showed that
the effect was carried by an increased proportion of risky
choices in a single condition where the experimental
gamble also offers a large potential gain. This behavioural
pattern is probably best understood as reflecting a com-
bined effect of reduced sensitivity to cues of punishment
and increased sensitivity to reward.
Only little human research into potential acute effects of
cortisol on reward-driven behaviour has been reported.
Tops et al. (2006) reported increased approach-motivated
locomotor behaviour. Putman et al. (2007b) reported
increased selective processing of angry faces after cortisol
administration. This was assumed to reflect increased
socially agonistic motivational tendencies that have been
linked to approach- and reward-driven behaviour (van
Honk et al. 2001; d’Alfonso et al. 2000; Putman et al.
2004; Wirth and Schultheiss 2007; Beaver et al. 2008;
Hermans et al. 2008; Passamonti et al. 2008; Carver and
Harmon-Jones 2009). Most recently, van den Bos et al.
(2009) reported cortisol effects on another motivated
decision-making task (the Iowa gambling task or IGT;
Bechara et al. 1996) in participants who had been subjected
to a psychological stressor. The subjects with larger cortisol
responses to the stressor demonstrated a performance
pattern that reflects perseverance in making decisions that
not only yield high immediate reward but also result in
more severe punishment. Such a pattern of IGT perfor-
mance is typical for less anxiously inhibited more reward-
oriented participants (e.g. van Honk et al. 2002). Therefore,
it is highly likely that the data reported by van den Bos et
al. truly reflect effects of neuroendocrine agents involved in
the stress response and do not merely result as a
psychological response to the stressor. As such, their results
showing that higher cortisol levels predict more reward and
less punishment sensitivity are very much in line with the
present results. Finally, it has also been demonstrated that
administration of GCs increases self-administration of
psychostimulant drugs in rodents (Marinelli et al. 1998;
Mantsch and Katz 2007). A mechanism likely causing such
increased reward-seeking behaviour is GCs’ acute increase
of DA activity in the nucleus accumbens (NAcc), a vital
structure in the mesolimbic DA reward pathway (Marinelli
and Piazza 2002).
It seems quite possible then that relations between HPA
activity and pathological gambling (Wohl et al. 2008),
reward-driven and punishment-insensitive effects as ob-
Fig. 1 a Median proportionate choice scores and 25th and 75th
percentile limits for the eight experimental conditions. b Proportionate
choice scores for the high-risk situation where there is a large
probability of losing. For wins only and losses only, a higher score
indicates fewer participants chose to gamble instead of taking the
guaranteed win/loss. For all other measures, a higher score indicates
that participants more often chose experimental gambles over than
control gambles
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served by van den Bos et al., as well as the present results,
may be mediated by cortisol’s effect on NAcc DA activity.
Both the results of van den Bos et al. with the IGT and the
present results constitute an effect of cortisol on conditions
that simultaneously present a great risk and a great reward
cue. These are high arousing situations likely involving
simultaneous activation of neuroendocrine stress and
reward systems, both of which may be involved in
cortisol’s apparent stress-reducing effects. CRF, an impor-
tant neurohormone in the HPA stress cascade, has been
reported to have anxiogenic and depressogenic effects in
non-human primates (Strome et al. 2002), so increased
negative feedback resulting from our cortisol administration
may influence sensitivity to arousing cues of punishment.
Cortisol itself may also affect stress directly via stimulation
of GRs in limbic-prefrontal emotion regulation circuits (e.g.
de Kloet et al. 1999, 2005; Etkin et al. 2006; Liberzon et al.
2007). Alternatively, potentially anxiolytic interactions
between cortisol and its metabolites and GABA are
possible. (see Putman et al. 2007a). Finally, NAcc DA-
stimulating properties of cortisol have been proposed to
reduce stress through reward sensitisation (see Marinelli
and Piazza 2002). Possibly then, subtle effects of cortisol
on the decision-making task may only become observable
when both reward and stress systems involved in cortisol’s
affective properties are triggered, as also inherent in
performance of the IGT. Of course, all this remains
speculative, and it is possible that different mechanisms
are needed to explain the diversity of abovementioned
findings. An alternative to this speculative explanation of
the apparent specificity of the observed effect is to
interpret it as a mere chance finding in a single
condition. However, the effect remains significant after
chance-level correction, so the finding is statistically
sound and not likely spurious.
Several factors limit the interpretation of this study and
its results. Firstly, in order to exclude possibly confounding
influences of menstrual endocrine fluctuations and as a
replication of several relevant previous studies (e.g. Putman
et al. 2007a, b; Oei et al. 2009), only men were tested.
These results may not generalise to women. Secondly, only
a dose of 40 mg of cortisol was tested. Because the relation
between cortisol levels and (cognitive) behaviour may be
nonlinear (see e.g. Buchanan et al. 2001; Lupien et al.
1999), future studies may address the issue of dose–
response relation.
The potential therapeutic value of GC administration in
the treatment of anxiety disorders is an important current
issue (Aerni et al. 2004; Soravia et al. 2006; Schelling et al.
2006; de Quervain and Margraf 2008). The present study
adds to our knowledge of possible anxiolytic properties of
cortisol by being the first to demonstrate that cortisol affects
more complex-motivated behaviour in healthy subjects.
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